摘要
目的验证氟西汀在治疗持续的躯体形式疼痛障碍中的镇痛疗效及其产生的不良反应。方法选取78例持续的躯体形式疼痛障碍患者,并将其随机分为氟西汀组和安慰剂组进行对照观察,评估治疗前(0周)及治疗后1,2,4,8周疼痛量表(MOSPM)和药物不良反应量表(TESS)评分,评估氟西汀的疗效及不良反应。结果安慰剂组MOSPM评分治疗前为(64.68±24.95)分,治疗后8周显著降低为(55.31±24.83)分,差异有显著性意义(P<0.01);氟西汀组MOSPM评分治疗前为(59.62±21.75)分,治疗后8周显著降低为(33.07±19.01)分,差异有显著性意义(P<0.01);治疗第2周末,两组间各时间点比较,差异均有显著性意义(P<0.01),氟西汀组有轻度厌食、失眠、口干、头痛、恶心等不良反应,治疗第8周末,不良反应明显缓解。结论氟西汀组治疗持续的躯体形式疼痛障碍有良好的治疗效果,且不良反应较轻。
[ Objective ] To explore clinical effect and adverse reaction of fluoxetine in the treatment of persist somatoform pain disorder（PSPD）. [ Methods ] 78 cases patients with persistent somatoform pain disorder were sdected in author＇ s hospital divided into two groups randomly, 39 cases in the control group were treaded with placebo, 39 cases in ohservalion growp were treated with fiuoxetine. Medical Outcomes Study Pain Measurement （MOSPM）and treatment emergent symptoms scale TESS for severity of PSPD. [ Resluts ] The HAMD scores of two groups after treatment of 2 weeks, 4 weeks, 6 weeks showed significant difference, were lower then before, has statistically significant（P〈0.01）. After 8 weeks of treatment, control group were （55.31 ± 24.83）,lower than 0 weeks（64.68 ± 24.95）; fiuoxetin group were（33.07 ± 19.01）, lower than 0 weeks（59.62 ± 21.75）; All the symptom improved after treatment. The fluoxetine group mild loss of appetite, insomnia, dry mouth, headache, nausea and other adverse reactions, but significantly alleviate the adverse reactions after treatment of 8 week. [ Conclusion ] Persistent somatoform pain disorder with fluoxetine treatment in effect can significantly improve patient compliance.
出处
《中国医学工程》
2013年第9期10-11,共2页
China Medical Engineering
关键词
氟西汀
持续的躯体形式疼痛障碍
疗效
不良反应
fluoxetine
persist somatoform pain disorder
clinical effect
adverse reaction
